List of Excipients in Branded Drug LEVOXYL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	LEVOXYL	levothyroxine sodium	54868-4087	CALCIUM SULFATE DIHYDRATE
Physicians Total Care Inc	LEVOXYL	levothyroxine sodium	54868-4087	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	LEVOXYL	levothyroxine sodium	54868-4087	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	LEVOXYL	levothyroxine sodium	54868-4087	FD&C YELLOW NO. 6
Physicians Total Care Inc	LEVOXYL	levothyroxine sodium	54868-4087	MAGNESIUM STEARATE
Physicians Total Care Inc	LEVOXYL	levothyroxine sodium	54868-4087	SODIUM BICARBONATE

LEVOXYL Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Levoxyl is a levothyroxine sodium tablet marketed by Pfizer. Its active ingredient is long generic, and the principal commercial opportunity is not composition-of-matter exclusivity. It is formulation execution: dose uniformity, stability, excipient tolerability, supply reliability, packaging, and controlled substitution in a narrow-therapeutic-index product.

Levoxyl’s commercial position is constrained by extensive generic competition and limited patent protection. A differentiated excipient platform could support a new levothyroxine product through an ANDA, 505(b)(2) application, or licensed technology, but the regulatory burden is high because small differences in formulation can affect dissolution, absorption, and thyroid-stimulating hormone control.

What is Levoxyl and who markets it?

Levoxyl is an oral tablet containing levothyroxine sodium, the synthetic sodium salt of the thyroid hormone thyroxine, or T4. Pfizer markets the product in the United States under NDA 021301. It is approved for replacement therapy in hypothyroidism and for suppression of thyrotropin in selected thyroid-related indications.[1]

Attribute	Levoxyl status
Active ingredient	Levothyroxine sodium
Dosage form	Oral tablet
U.S. sponsor	Pfizer
FDA application	NDA 021301
Therapeutic category	Thyroid hormone replacement
Regulatory classification	Prescription drug
Commercial market	Brand and multiple generic levothyroxine tablets
Patent position	No meaningful active composition-of-matter exclusivity
Substitution sensitivity	High because levothyroxine is treated as a narrow-therapeutic-index drug

Levoxyl is available across multiple strengths, generally ranging from 25 mcg to 200 mcg. The product uses strength-specific tablet colors and markings to distinguish doses. Correct strength identification is commercially important because levothyroxine is dosed in micrograms and small dose errors can produce clinically relevant effects.

What excipients are used in Levoxyl tablets?

The Levoxyl label identifies a tablet excipient system that includes colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, sodium bicarbonate, and talc. Color additives vary by tablet strength.[1]

Excipient	Functional role	Commercial relevance
Colloidal silicon dioxide	Glidant and flow aid	Supports powder flow and content uniformity
Crospovidone	Superdisintegrant	Controls tablet breakup and dissolution
Magnesium stearate	Lubricant	Reduces sticking and tooling friction
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Povidone	Binder	Improves granule or tablet cohesion
Sodium bicarbonate	Processing or microenvironmental modifier	May affect tablet characteristics and stability
Talc	Glidant or anti-adherent	Supports compression and manufacturing performance
Colorants	Identification by strength	Reduces dispensing and administration errors

The formulation is commercially relevant because levothyroxine has a narrow dosing range and low active-ingredient loading. A 25 mcg tablet contains very little active pharmaceutical ingredient relative to total tablet mass. The excipient system therefore has a direct effect on blend uniformity, compression, disintegration, dissolution, and dose reproducibility.

How strong is the Levoxyl formulation and excipient patent estate?

Levoxyl’s current commercial value is not based on a strong active patent estate. Levothyroxine sodium has been used for decades, and generic manufacturers have broad access to the active ingredient and tablet dosage form.

The main barriers are technical and regulatory:

1. Demonstrating consistent potency across a wide strength range.
2. Controlling degradation and potency loss during shelf life.
3. Matching dissolution behavior against the reference product.
4. Producing reliable low-dose tablets.
5. Managing interchangeability and switching concerns.
6. Maintaining supply of pharmaceutical-grade excipients and colorants.

The Orange Book remains the controlling source for current patent and regulatory-exclusivity listings. Public FDA product information does not establish a commercially significant active patent barrier around the Levoxyl excipient system.[2]

Are Levoxyl excipients protected by formulation patents?

A formulation using common excipients such as microcrystalline cellulose, magnesium stearate, povidone, crospovidone, and colloidal silicon dioxide is difficult to protect broadly. A potential patent strategy would require a specific and non-obvious combination tied to measurable performance, such as:

• Improved potency stability under accelerated conditions.
• Reduced degradation caused by humidity, light, oxygen, or excipient interaction.
• More consistent dissolution across strengths.
• Reduced dose variability in low-strength tablets.
• A defined particle-size distribution or compression profile.
• A novel coating, barrier layer, or packaging system.
• Reduced sensitivity to administration with food, calcium, iron, or acid-suppressing products.

Broad claims covering ordinary tablet excipients are vulnerable to anticipation and obviousness challenges. Narrow claims supported by comparative stability, dissolution, or pharmacokinetic data are more defensible.

What excipient strategy can improve Levoxyl economics?

The strongest strategy is to treat excipients as a controlled performance system rather than as low-cost inactive ingredients.

1. Improve low-dose content uniformity

Low-strength levothyroxine products create the greatest manufacturing challenge. The active ingredient must be uniformly distributed through the blend or granulation. A commercial platform could use:

• Ordered mixing of levothyroxine onto a carrier.
• Controlled particle-size matching between API and diluent.
• Geometric dilution.
• A validated high-shear blending process.
• Granulation that limits segregation.
• In-process near-infrared monitoring.
• Dedicated low-dose premixes.

A supplier that provides a qualified levothyroxine premix with validated uniformity could capture value from generic manufacturers and specialty developers. The opportunity is strongest for 25 mcg and lower-dose products, where content uniformity risk is highest.

2. Reduce excipient-related stability risk

Levothyroxine products can experience potency and degradation problems associated with moisture, oxygen, light, heat, and excipient interactions. An excipient program should screen:

• Moisture content and water activity.
• Peroxide levels in polymeric excipients.
• Reducing or oxidizing impurities.
• Residual solvents.
• Trace metals.
• pH and microenvironmental effects.
• Packaging permeability.

Low-peroxide grades of povidone, controlled-moisture microcrystalline cellulose, and qualified magnesium stearate can reduce batch-to-batch variability. Excipient supplier qualification is commercially important because an apparently minor change in grade or source may alter tablet performance.

3. Optimize disintegration and dissolution

Crospovidone, sodium starch glycolate, croscarmellose sodium, and related superdisintegrants can produce different dissolution profiles even at similar concentrations. A reformulation program should measure:

• Disintegration time.
• Dissolution at multiple pH conditions.
• Dissolution after storage.
• Tablet hardness and friability.
• Sensitivity to lubricant overmixing.
• Impact of compression force.
• Performance across all marketed strengths.

The commercial goal is not necessarily the fastest dissolution. It is a reproducible profile that remains within regulatory specifications and avoids unexpected pharmacokinetic shifts.

4. Develop a lower-risk excipient platform

A manufacturer can differentiate through excipient simplicity. A short, tightly controlled excipient list may reduce:

• Supplier qualification costs.
• Analytical testing requirements.
• Labeling complexity.
• Risk of excipient substitutions.
• Manufacturing variability.
• Patient concerns about dyes or animal-derived materials.

A dye-free platform could target patients who prefer fewer colorants or who have sensitivity concerns. The tradeoff is that color coding helps prevent strength-selection errors. A dye-free product would need strong tablet imprinting, packaging, and dispensing controls.

What commercial opportunities exist beyond the Levoxyl tablet?

Which levothyroxine dosage forms compete with Levoxyl?

The commercial field includes conventional tablets, soft-gel capsules, oral solutions, and compounded preparations. Tablets remain the dominant dosage form because they are inexpensive, widely available, and familiar to prescribers and pharmacists.

Dosage form	Commercial advantage	Main limitation
Conventional tablet	Low cost and broad pharmacy access	Food, gastric pH, and excipient effects
Soft-gel capsule	Potentially lower sensitivity to some dissolution conditions	Higher manufacturing and packaging cost
Oral solution	Useful for selected patients and dose flexibility	More complex stability and packaging requirements
Compounded liquid	Custom dosing	Variable quality and limited scalability
Orally disintegrating tablet	Administration convenience	Requires robust dose uniformity and moisture control

Soft-gel and liquid formulations offer the clearest differentiation opportunity. They may target patients with swallowing difficulty, malabsorption, polypharmacy, feeding tubes, or inconsistent thyroid control. Evidence must show that the product improves a clinically relevant problem rather than merely changing the dosage form.

Can a reformulated Levoxyl product use a 505(b)(2) pathway?

A materially different dosage form, excipient system, or delivery technology could potentially be developed under the 505(b)(2) pathway, depending on the product’s differences and the reliance placed on existing findings. The pathway may be relevant for:

• Oral solution.
• Soft-gel capsule.
• Orally disintegrating tablet.
• Modified excipient system.
• New package configuration.
• Improved administration for patients with swallowing or absorption problems.

The pathway does not eliminate the need for comparative pharmacokinetic, stability, dose-proportionality, and clinical bridging work. Levothyroxine’s narrow therapeutic index increases scrutiny of product-to-product differences.

What FDA regulatory issues affect Levoxyl excipient innovation?

FDA treats levothyroxine as a narrow-therapeutic-index drug and has issued product-specific recommendations for demonstrating therapeutic equivalence and bioequivalence.[3] The regulatory issues most relevant to excipient strategy are:

• Dose uniformity across strengths.
• Potency throughout shelf life.
• Comparative dissolution.
• Steady-state pharmacokinetics.
• Control of T4 and T3-related parameters where applicable.
• Product labeling for administration with food.
• Interactions with calcium, iron, antacids, bile-acid sequestrants, and proton-pump inhibitors.
• Switching between products.
• Consistent tablet appearance and imprinting.

An excipient change in an approved product may require a post-approval supplement. A generic applicant must demonstrate bioequivalence to the reference listed drug under the applicable FDA framework. A product that changes absorption could require a more extensive clinical package.

What is the Orange Book and generic-entry status for Levoxyl?

Levoxyl competes in a mature generic market. The FDA Orange Book identifies reference-listed drugs, approved generic equivalents, patent certifications, and regulatory exclusivities.[2]

Issue	Levoxyl commercial implication
Composition-of-matter patent	Not a meaningful barrier
Generic tablets	Broad competition
Paragraph IV risk	More relevant to any new formulation or listed patent than to old levothyroxine chemistry
Authorized generic risk	Relevant if Pfizer or a partner commercializes a brand-equivalent product
Therapeutic-equivalence concern	High because switching can change thyroid control
Regulatory exclusivity	Product-specific and must be verified in the current Orange Book
Entry strategy	Cost, supply reliability, dosage-form differentiation, or clinical niche

A new formulation with defensible patents could face Paragraph IV challenges if it lists patents in the Orange Book. For the legacy Levoxyl tablet, generic entry is primarily a commercial and manufacturing issue rather than a patent-clearance problem.

Which companies challenge or compete with Levoxyl?

Levoxyl competes with branded and generic levothyroxine products, including Synthroid, Unithroid, Tirosint, generic levothyroxine tablets, and liquid or soft-gel products. The competitive groups are:

• Large generic manufacturers with low-cost tablet production.
• Branded levothyroxine manufacturers with prescriber recognition.
• Specialty companies selling soft-gel or liquid products.
• Contract manufacturers with high-containment or low-dose blending capabilities.
• Excipient suppliers offering controlled grades and co-processed materials.

The strongest commercial differentiation is likely to come from a formulation that demonstrates a defined clinical or operational benefit, such as easier administration, more reliable exposure in a defined patient segment, or lower manufacturing variability.

What patent litigation and settlement risks affect Levoxyl?

No active Levoxyl-specific patent litigation or settlement can be established from the FDA product and Orange Book materials cited here. The relevant litigation risk for a new product would arise from:

• Patent claims covering a levothyroxine soft-gel or liquid formulation.
• Stability claims based on specific excipient combinations.
• Delivery technologies that reduce food or gastric-pH effects.
• Manufacturing patents covering low-dose uniformity.
• Trade-secret disputes involving blending, granulation, or packaging processes.
• Trademark or product-appearance disputes involving tablet color and imprinting.

A formulation patent should be drafted around measurable performance and manufacturing controls. Claims directed only to the presence of familiar excipients would face substantial validity risk.

How should companies monetize a Levoxyl excipient platform?

Potential commercial models include:

Model	Revenue source	Best use case
Excipient supply agreement	Per-unit or volume-based sales	Generic tablet manufacturers
Co-processed excipient license	Royalty on product sales	Improved blending or compression
Formulation license	Upfront payment plus royalties	Soft-gel, liquid, or ODT platform
Contract development	Development fees and milestone payments	Sponsors lacking levothyroxine expertise
Finished-dose manufacturing	Product margin	Specialty or private-label products
Packaging technology	Unit-dose or moisture-barrier premium	Stability-sensitive formulations
Co-development partnership	Shared development and commercialization	505(b)(2) product with clinical differentiation

The highest-value asset is likely to be a validated, scalable formulation package with comparative dissolution, accelerated stability, manufacturing data, and a clear regulatory pathway. A raw excipient ingredient without formulation know-how is easier to substitute and supports lower margins.

What is the revenue exposure and market outlook?

Levoxyl-specific revenue is not separately disclosed in Pfizer’s public financial reporting. The commercial exposure is therefore best assessed through product position rather than a verified brand-sales figure.

The market has several favorable characteristics:

• Chronic, lifelong treatment for most patients.
• High prescription volume.
• Multiple strengths.
• Repeated refills.
• Large switching-sensitive patient population.
• Continuing need for stable supply.

The constraints are equally clear:

• Low unit prices for generic tablets.
• Strong pharmacy substitution.
• Limited patient willingness to pay for ordinary tablets.
• Mature API and manufacturing technology.
• Regulatory scrutiny of formulation changes.
• Difficulty proving superiority without clinical data.

A premium strategy is more credible for liquid, soft-gel, pediatric, geriatric, feeding-tube, malabsorption, or excipient-restricted populations than for another conventional tablet.

How does Levoxyl compare with Synthroid and Tirosint?

Product	Dosage form	Differentiation	Excipient opportunity
Levoxyl	Tablet	Established tablet brand	Stability, uniformity, dye-free or simplified excipient system
Synthroid	Tablet	Large branded presence	Dose consistency and brand continuity
Tirosint	Soft-gel capsule and related formulations	Reduced excipient load and alternative delivery	Capsule shell, fill uniformity, moisture control
Generic levothyroxine	Mostly tablets	Price and access	Low-cost manufacturing and supply reliability

Levoxyl’s most defensible strategy is to protect product continuity and manufacturing quality while exploring a differentiated dosage form. Competing directly with low-cost generics on tablet price is less attractive than supplying a superior formulation platform or targeting patients for whom tablet administration is problematic.

What generic launch scenarios exist for improved Levoxyl formulations?

Scenario 1: Conventional tablet generic

This is the lowest-cost path and the most competitive. Success depends on manufacturing scale, supply reliability, low defect rates, and pharmacy contracting.

Scenario 2: Formulation-specific generic

A sponsor could develop a tablet with a distinct excipient system, but differentiation would be limited unless the formulation improves stability, tolerability, or dose control. Patent protection would likely be narrow.

Scenario 3: Soft-gel or liquid 505(b)(2)

This offers greater commercial differentiation and potentially higher pricing. It also creates greater development, stability, packaging, and clinical risk.

Scenario 4: Specialty low-dose or pediatric product

A formulation optimized for microdosing, pediatric administration, feeding tubes, or dysphagia could command a premium if it solves a documented administration problem.

Key Takeaways

• Levoxyl is a levothyroxine sodium tablet marketed by Pfizer under NDA 021301.
• Its listed excipients include colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, sodium bicarbonate, talc, and strength-specific colorants.
• The strongest formulation opportunities involve content uniformity, stability, dissolution control, moisture protection, and simplified excipient systems.
• Levothyroxine’s narrow therapeutic index makes formulation changes commercially valuable but regulatorily difficult.
• The legacy tablet has limited practical patent protection and faces extensive generic competition.
• Soft-gel, liquid, orally disintegrating, pediatric, and feeding-tube products offer more attractive differentiation than another standard tablet.
• Excipient suppliers can monetize validated premixes, low-peroxide grades, co-processed systems, and formulation licenses.
• Levoxyl-specific revenue is not separately disclosed by Pfizer, so commercial value should be assessed through market position, dosage-form differentiation, and manufacturing economics.

FAQs

Can Levoxyl be reformulated without changing the active ingredient?

Yes. A sponsor can change excipients or dosage form while retaining levothyroxine sodium, but the regulatory pathway depends on the extent of the change and whether the product relies on an existing FDA finding.

Are Levoxyl tablets lactose-free?

The cited Levoxyl ingredient list does not identify lactose. Product labeling should be checked for the specific strength and current manufacturing version because inactive ingredients can change.

Can a low-peroxide excipient improve levothyroxine stability?

It can reduce one potential source of oxidative stress, but the benefit must be demonstrated through comparative stability, impurity, potency, and dissolution data.

Is a liquid levothyroxine product commercially attractive?

Yes, particularly for patients with swallowing difficulty, feeding tubes, malabsorption concerns, or complex administration requirements. The product requires stronger packaging and stability controls than a conventional tablet.

Can an excipient supplier obtain patent protection for a Levoxyl-compatible formulation?

Yes, but broad claims to common excipients are unlikely to be strong. The most defensible claims would link a defined excipient system or manufacturing process to demonstrated stability, dose uniformity, dissolution, or pharmacokinetic performance.

References

1. Pfizer Inc. (2022). Levoxyl (levothyroxine sodium) tablets: Prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). Product-specific guidance for levothyroxine sodium. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs